Brief: Celularity Announces Treatment Of First Patient In Phase 1/2A Clinical Trial For Nk Cell Therapy Cynk-101, In Development For The First-Line Treatment Of Advanced Her2 Positive Gastric And Gastroesophageal Junction (G/Gej) Cancers
27/07/2022 13:39
Celularity Inc CELU.O :
* CELULARITY ANNOUNCES TREATMENT OF FIRST PATIENT IN PHASE
1/2A
CLINICAL TRIAL FOR NK CELL THERAPY CYNK-101, IN DEVELOPMENT FOR
THE FIRST-LINE TREATMENT OF ADVANCED HER2 POSITIVE GASTRIC AND
GASTROESOPHAGEAL JUNCTION (G/GEJ) CANCERS
Source text for Eikon: ID:nGNX2fRtl
Further company coverage: CELU.O
Recent news on Celularity
See all newsU.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform